Skip to main content
  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

AACR logo

  • Register
  • Log in
  • My Cart
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • CCR Focus Archive
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Breast Cancer
      • Clinical Trials
      • Immunotherapy: Facts and Hopes
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in
  • My Cart

Search

  • Advanced search
Clinical Cancer Research
Clinical Cancer Research
  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • CCR Focus Archive
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Breast Cancer
      • Clinical Trials
      • Immunotherapy: Facts and Hopes
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

Advances in Brief

Improved Cytotoxic Activity toward Cell Lines and Fresh Leukemia Cells of a Mutant Anti-CD22 Immunotoxin Obtained by Antibody Phage Display

Giuliana Salvatore, Richard Beers, Inger Margulies, Robert J. Kreitman and Ira Pastan
Giuliana Salvatore
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Richard Beers
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Inger Margulies
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Robert J. Kreitman
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ira Pastan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI:  Published April 2002
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Article Figures & Data

Figures

  • Tables
  • Fig. 1.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Fig. 1.

    Binding of phage to Daudi cells. Phage were prepared from single colonies eluted after the second round of panning and titered as described in “Materials and Methods.” Five × 105 Daudi cells were incubated with 8 × 108 phage for 60 min at room temperature; washed with DPBS + 0.5 mm EDTA + 0.5% BSA, and incubated with 5 μg of anti-M13 antibody (Amersham) for another 20 min. Successively, a FITC-conjugated goat antimouse IgG (H+L) antibody was added to the cells, and analysis was performed using a flow cytometer (Becton and Dickinson). A, cell, cells were not incubated with phage or with anti-M13 antibody but only with FITC-conjugated goat antimouse IgG (H+L) antibody; GSSY, WT phage; GSSY+IT, 63 μg of RFB4 immunotoxin were added, together with GSSY phage to Daudi cells, and processed because the sample incubated only with the phage. B, cell, cells were not incubated with phage or with anti-M13 antibody but only with FITC-conjugated goat antimouse IgG (H+L) antibody; GSSY, WT phage; line A, mutant phage A, binder; line B, mutant phage B, binder; line C, mutant phage C, binder.

  • Fig. 2.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Fig. 2.

    Cytotoxicicity assay on cells isolated from patient 1. Ficoll-purified mononuclear cells from the patient were incubated with immunotoxins for 3 days at 37°C and pulsed with [3H]leucine for 6–8 h. Radiolabeled material was captured on filter-mats and counted in a Betaplate scintillation counter (Wallac). The graph shows, protein synthesis as measured by cpm of [3H]leucine incorporated into protein. The horizonial dashed line indicates, 50% inhibition of protein synthesis, which is halfway between the level of incorporation in the absence of toxin and that in the presence of 10 μg/ml of cycloheximide.

  • Fig. 3.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Fig. 3.

    Biacore sensograms of RFB4(Fv)-PE38 mutants. Binding profile of WT immunotoxin GSSY is compared with mutants GTTW, GTHW, and GYNW. RITs were diluted to 25 μg/ml in HEPES buffered saline buffer and injected over a chip surface containing CD22. Binding kinetics were analyzed using BIA evaluation 2.1 software. Y axis, the resonance units bound. X axis, the time in seconds.

Tables

  • Figures
  • Table 1

    DNA and amino acids sequences of CDR3 heavy chain RFB4

    The nucleotide and amino acid sequence of the entire CDR3 heavy chain is shown. Hot spots with the sequence Pu-G-Py-A/T are underlined. The amino acids mutagenized are in bold. The residues are numbered according to the Kabat database (21) .

    9596979899100100A100B100C100D100E100F101102
    HSGY G S S Y GVLFAY
    CATAGT GGC TAC GGT AGTAGCTACGGG GTT TTGTTTGCTTAC
  • Table 2

    Sequences of mutant phage obtained after panning

    Amino acid sequences of mutant phage isolated after two rounds of panning are listed. The entire Fv of each phage was sequenced. Only amino acids in the target region are shown. Each residue is numbered according to the Kabat database (21) .

    99100100A100B
    GSSYa
    GTHWb
    GYNWb
    GTTWb,c
    GSTYb
    GKNRb,c
    GSTRd
    GHTF
    GNRY
    GTAY
    GTNY
    GLHY
    GFLY
    GSRY
    GRNY
    GVHR
    GALR
    GVRA
    GTAK
    GRTS
    • a WT.

    • b Immunotoxin made.

    • c Clone found three times.

    • d Clone found two times.

  • Table 3

    Cytotoxic activity (IC50) in ng/ml of selected RFB4 (Fv)-PE38 mutants on six different CD22-positive cell lines

    Cells were seeded at 5 × 104/well in 96-well plate 24 h before the assay. Immunotoxins were added to the plate, and cells were incubated at 37°C for 20 h and then were pulsed with [3H]leucine for 2 h. [3H]leucine incorporations were determined. Each assay was done in triplicate, and, except as noted below, at least three different assays were performed with each cell line. IC50 (expressed in ng/ml) is the toxin concentration that reduced incorporation of radioactivity by 50% compared with the cells that were not treated with the toxin. Mean values of three experiments ± SD are shown. SDs are not listed when the immunotoxins were tested only once. Below each IC50 is the significance in its difference from GSSY (WT) and GTHW when differences by Student’s t test were significant (P < 0.05).

    JD38Ca46RajiDaudiNamalwaRamos
    GSSY (WT) vs. GTHW2.3 ± 0.53.1 ± 0.25.1 ± 0.158.1 ± 2.310.6 ± 1.2252 ± 3
    P < 0.01P < 0.05P < 0.01P < 0.01P < 0.01P < 0.01
    GTHW vs. WT0.2 ± 0.091.4 ± 0.51 ± 0.141.7 ± 0.12.8 ± 0.432 ± 3
    P < 0.01P < 0.05P < 0.01P < 0.01P < 0.01P < 0.01
    GYNW vs. WT vs. GTHW0.6 ± 0.10.80.6 ± 0.072.1 ± 0.55.6 ± 3.3N.D.a
    P < 0.01P < 0.01P < 0.01
    P < 0.01P < 0.05
    GTTW vs. WT vs. GTHW0.7 ± 0.031.7 ± 0.42.75 ± 0.32.0 ± 1.25.3 ± 0.2N.D.
    P < 0.01P < 0.05P < 0.01P < 0.01P < 0.01
    P < 0.01P < 0.01P < 0.01
    GSTY vs. WT vs. GTHW1.124.18.5 ± 0.79.5N.D.
    P < 0.01
    GKNR vs. WT vs. GTHW561055 ± 725N.D.
    P < 0.01
    P < 0.01
    • a N.D., not determined.

  • Table 4

    Cytotoxic activity (IC50) in ng/ml of mutant immunotoxins on patient cells

    Patient 1Patient 2Patient 3Patient 4Patient 5
    GSSY (WT) vs. GTHW>1000490 ± 7034 ± 56.7 ± 2.3>1000
    P < 0.01P < 0.01P < 0.01P < 0.01P < 0.01
    GTHW vs. GSSY (WT)29 ± 1022 ± 21.5 ± 0.4<128 ± 6
    P < 0.01P < 0.01P < 0.01P < 0.01P < 0.01
    GYNW vs. GSSY (WT) vs. GTHW105 ± 4840 ± 53.4 ± 0.7N.D.a41 ± 2
    P < 0.01P < 0.01P < 0.01
    P < 0.01P < 0.05P < 0.05
    GTTW vs. GSSY (WT) vs. GTHW>100095 ± 98.5 ± 31.5 ± 0.676 ± 9
    P < 0.01P < 0.01P < 0.01P < 0.05P < 0.01
    P < 0.01P < 0.01P < 0.01P < 0.01
    GSTY vs. GSSY (WT) vs. GTHWN.D.N.D.15 ± 22.1 ± 0.7129 ± 50
    P < 0.01P < 0.01P < 0.05P < 0.01
    P < 0.01P < 0.05
    • Ficoll-purified mononuclear cells from patients were obtained by an approved protocol at the NIH. Cells were incubated with immunotoxins for 3 days at 37°C and pulsed with [3H]leucine for 6–8 h; protein synthesis was measured. IC50s are expressed in ng/ml; SDs are shown. Each assay was done in triplicate. Diagnosis for patients 1, 2, 3, and 5 was CLL; diagnosis for patient 4 was HCL variant.

    • a N.D., not determined.

    • Significance in difference between IC50s as in Table 3<$REFLINK> .

  • Table 5

    Summary of BIAcore analysis mutants of RFB4-PE38

    Binding kinetics were analyzed on a BIAcore 2000 Biosensor (BIAcore). On and off rates were measured by injecting immunotoxins at a concentration of 380 nm over a CM5 sensor chip (BIAcore) containing immobilized CD22. Bound material was allowed to dissociate for 5 min or more.
    ImmunotoxinKon (M−1S−1)Koff (S−1)Kda (nm)
    GSSY (WT)2.08 × 1041.77 × 10−385
    GTHW3.27 × 1042.07 × 10−46
    GYNW1.84 × 1041.91 × 10−410
    GTTW2.62 × 1046.5 × 10−424
    GSTY3.15 × 1041.55 × 10−349
    • a Kd was calculated by dividing Koff by Kon.

PreviousNext
Back to top
April 2002
Volume 8, Issue 4
  • Table of Contents

Sign up for alerts

View this article with LENS

Open full page PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Clinical Cancer Research article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Improved Cytotoxic Activity toward Cell Lines and Fresh Leukemia Cells of a Mutant Anti-CD22 Immunotoxin Obtained by Antibody Phage Display
(Your Name) has forwarded a page to you from Clinical Cancer Research
(Your Name) thought you would be interested in this article in Clinical Cancer Research.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Improved Cytotoxic Activity toward Cell Lines and Fresh Leukemia Cells of a Mutant Anti-CD22 Immunotoxin Obtained by Antibody Phage Display
Giuliana Salvatore, Richard Beers, Inger Margulies, Robert J. Kreitman and Ira Pastan
Clin Cancer Res April 1 2002 (8) (4) 995-1002;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Improved Cytotoxic Activity toward Cell Lines and Fresh Leukemia Cells of a Mutant Anti-CD22 Immunotoxin Obtained by Antibody Phage Display
Giuliana Salvatore, Richard Beers, Inger Margulies, Robert J. Kreitman and Ira Pastan
Clin Cancer Res April 1 2002 (8) (4) 995-1002;
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Introduction
    • Materials and Methods
    • Results
    • Discussion
    • Acknowledgments
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • PDF
Advertisement

Related Articles

Cited By...

More in this TOC Section

  • Pharmacodynamic Evaluation of CCI-779, an Inhibitor of mTOR, in Cancer Patients
  • Zoledronic Acid Induces Significant and Long-Lasting Modifications of Circulating Angiogenic Factors in Cancer Patients
  • CpG Island Methylator Phenotype Is an Independent Predictor of Survival Benefit from 5-Fluorouracil in Stage III Colorectal Cancer
Show more Advances in Brief
  • Home
  • Alerts
  • Feedback
  • Privacy Policy
Facebook  Twitter  LinkedIn  YouTube  RSS

Articles

  • Online First
  • Current Issue
  • Past Issues
  • CCR Focus Archive
  • Meeting Abstracts

Info for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians

About Clinical Cancer Research

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2021 by the American Association for Cancer Research.

Clinical Cancer Research
eISSN: 1557-3265
ISSN: 1078-0432

Advertisement